Literature DB >> 1970724

Non-proteolytic activation of cellular protransglutaminase (placenta macrophage factor XIII).

J Polgár1, V Hidasi, L Muszbek.   

Abstract

Plasma Factor XIII is a zymogen (plasma protransglutaminase) with the tetrametric structure A2B2, whereas the cellular protransglutaminase, i.e. Factor XIII in the platelet and monocyte/macrophage, consists exclusively of A subunits (A2). It is generally accepted that at Ca2+ concentrations comparable with that in plasma the proteolytic removal of an N-terminal activation peptide is the prerequisite for the Ca2(+)-induced formation of a catalytically active configuration of subunit A. In this study it was demonstrated that at high concentrations NaCl or KCl induced a non-proteolytic activation of cellular (placental macrophage) but not plasma protransglutaminase. The activation depended on time and salt concentration, and Ca2+, in the range 0-20 mM, greatly enhanced the activation process. At 1.25 M-NaCl maximal activation occurred within 60 min in the presence of 2 mM-CaCl2, and even at physiological NaCl concentration a slow progressive activation could be observed in the presence of Ca2+. The specific activity of salt-activated Factor XIII was 1.5-2.0-fold higher than that obtained after thrombin activation. The non-proteolytic activation of cellular protransglutaminase was abolished by the addition of subunit B of plasma Factor XIII in stoichiometric amount, which suggests that (one of) the physiological function(s) of the B subunit in plasma Factor XIII is to prevent the slow spontaneous activation of A subunit that would occur in a plasmatic environment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1970724      PMCID: PMC1131328          DOI: 10.1042/bj2670557

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  23 in total

1.  [An unknown action of blood platelets; preliminary communication].

Authors:  K BULUK
Journal:  Pol Tyg Lek (Wars)       Date:  1955-02-07

2.  Human Factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin.

Authors:  M L Schwartz; S V Pizzo; R L Hill; P A McKee
Journal:  J Biol Chem       Date:  1973-02-25       Impact factor: 5.157

3.  Calcium-induced dissociation of human plasma factor XIII and the appearance of catalytic activity.

Authors:  R D Cooke
Journal:  Biochem J       Date:  1974-09       Impact factor: 3.857

4.  The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  K Weber; M Osborn
Journal:  J Biol Chem       Date:  1969-08-25       Impact factor: 5.157

Review 5.  Molecular and catalytic properties of transglutaminases.

Authors:  J E Folk; S I Chung
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1973

6.  Factor XIII (fibrin-stabilizing factor).

Authors:  L Lorand; R B Credo; T J Janus
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

7.  Human factor XIII: fibrin-stabilizing factor.

Authors:  L Lorand; M S Losowsky; K J Miloszewski
Journal:  Prog Hemost Thromb       Date:  1980

8.  Calcium and the assays of human plasma clotting factor XIII.

Authors:  R D Cooke; J J Holbrook
Journal:  Biochem J       Date:  1974-07       Impact factor: 3.857

9.  Affinity chromatography of human plasma and platelet factor XIII on organomercurial agarose.

Authors:  J Mcdonagh; W G Waggoner; E G Hamilton; B Hindenbach; R P Mcdonagh
Journal:  Biochim Biophys Acta       Date:  1976-10-28

10.  Ca2+-related regulatory function of fibrinogen.

Authors:  R B Credo; C G Curtis; L Lorand
Journal:  Proc Natl Acad Sci U S A       Date:  1978-09       Impact factor: 11.205

View more
  15 in total

1.  Effect of factor XIII on endothelial barrier function.

Authors:  T Noll; G Wozniak; K McCarson; A Hajimohammad; H J Metzner; J Inserte; W Kummer; F W Hehrlein; H M Piper
Journal:  J Exp Med       Date:  1999-05-03       Impact factor: 14.307

2.  Reversible activation of cellular factor XIII by calcium.

Authors:  Gunhild Klarskov Kristiansen; Mette Dahl Andersen
Journal:  J Biol Chem       Date:  2011-01-18       Impact factor: 5.157

3.  Activation of factor XIII is accompanied by a change in oligomerization state.

Authors:  Boris A Anokhin; Vilius Stribinskis; William L Dean; Muriel C Maurer
Journal:  FEBS J       Date:  2017-10-03       Impact factor: 5.542

4.  Role of calcium in the conformational dynamics of factor XIII activation examined by hydrogen-deuterium exchange coupled with MALDI-TOF MS.

Authors:  Ricky T Woofter; Muriel C Maurer
Journal:  Arch Biochem Biophys       Date:  2011-05-26       Impact factor: 4.013

5.  Immunohistochemical detection of factor XIIIa and factor XIIIs in synovial membranes of patients with rheumatoid arthritis or osteoarthritis.

Authors:  A Plenz; P Fritz; G König; W Laschner; J G Saal
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

6.  Proteolytic and nonproteolytic activation mechanisms result in conformationally and functionally different forms of coagulation factor XIII A.

Authors:  Boris A Anokhin; William L Dean; Kerrie A Smith; Matthew J Flick; Robert A S Ariëns; Helen Philippou; Muriel C Maurer
Journal:  FEBS J       Date:  2019-08-28       Impact factor: 5.542

Review 7.  Fibrinogen and Factor XIII in Venous Thrombosis and Thrombus Stability.

Authors:  Alisa S Wolberg; Yaqiu Sang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2022-06-02       Impact factor: 10.514

8.  Airway factor XIII associates with type 2 inflammation and airway obstruction in asthmatic patients.

Authors:  Stephane Esnault; Elizabeth A Kelly; Ronald L Sorkness; Michael D Evans; William W Busse; Nizar N Jarjour
Journal:  J Allergy Clin Immunol       Date:  2015-10-30       Impact factor: 10.793

9.  Factor XIII B subunit polymorphisms and the risk of coronary artery disease.

Authors:  Zoltán A Mezei; Zsuzsanna Bereczky; Éva Katona; Réka Gindele; Emília Balogh; Szilvia Fiatal; László Balogh; István Czuriga; Róza Ádány; István Édes; László Muszbek
Journal:  Int J Mol Sci       Date:  2015-01-06       Impact factor: 5.923

10.  Monocytes Expose Factor XIII-A and Stabilize Thrombi against Fibrinolytic Degradation.

Authors:  Fahad S M Alshehri; Claire S Whyte; Ahmet Tuncay; Maria-Louise Williams; Heather M Wilson; Nicola J Mutch
Journal:  Int J Mol Sci       Date:  2021-06-19       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.